Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.12+0.04 (+0.66%)
Close on Nov 17, 2026Market cap $185.16MP/E –Yield –
Cartesian Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cartesian Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$78.61M. For fiscal 2025 it was -$79.40M. The highest annual figure on record is $34.07M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$79.40M | – |
| FY2024 | Dec 31, 2024 | -$32.77M | – |
| FY2023 | Dec 31, 2023 | -$51.37M | – |
| FY2022 | Dec 31, 2022 | -$32.83M | – |
| FY2021 | Dec 31, 2021 | -$61.47M | -280.4% |
| FY2020 | Dec 31, 2020 | $34.07M | – |
| FY2019 | Dec 31, 2019 | -$51.48M | – |
| FY2018 | Dec 31, 2018 | -$60.05M | – |
| FY2017 | Dec 31, 2017 | -$52.76M | – |
| FY2016 | Dec 31, 2016 | -$20.34M | – |
| FY2015 | Dec 31, 2015 | -$23.63M | – |
| FY2014 | Dec 31, 2014 | -$12.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.35M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$18.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.89M | -325.5% |
| Q2 FY2025 | Jun 30, 2025 | -$20.12M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.71M | – |
| Q3 FY2024 | Sep 30, 2024 | $7.49M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.22M | -335.3% |
| Q2 FY2023 | Jun 30, 2023 | -$9.91M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.06M | – |
| Q3 FY2022 | Sep 30, 2022 | $3.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.32M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.91M | -116.7% |
| Q2 FY2021 | Jun 30, 2021 | -$6.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.44M | – |
| Q3 FY2020 | Sep 30, 2020 | $65.35M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.83M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.91M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.09M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.60M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.81M | -1032.3% |
| Q3 FY2017 | Sep 30, 2017 | -$15.56M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.37M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.74M | – |
See a number that looks wrong?